Wayrilz: A New Twice-Daily Pill for Persistent and Chronic Immune Thrombocytopenia

Wayrilz (rilzabrutinib) is a new oral medicine for adults with persistent (lasting 3-12 months) or chronic (lasting more than 12 months) immune thrombocytopenia (ITP) who haven’t had success with a prior treatment. ITP is a… Read more

FDA Approves Ziftomenib: First Once-Daily Oral Therapy for Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

Ziftomenib, sold under the brand name Komzifti, is a new oral medicine approved to treat adults with a type of blood cancer called acute myeloid leukemia (AML). It’s meant for people whose AML has come… Read more

Tezspire: FDA Approves New Option for Chronic Sinus Inflammation With Nasal Polyps

Tezspire (tezepelumab-ekko) is a prescription medicine used to treat inflammatory conditions of the airways, such as severe asthma. The FDA has now approved it as an add-on treatment for adults and children aged 12 and… Read more

FDA Approves Wegovy as First Once-Weekly Injection for Obesity-Linked Liver Disease

Wegovy (semaglutide) is a once-weekly injection that was first approved in 2017 to help with weight loss and lower the risk of heart problems. Now, the FDA has approved it to treat a liver condition… Read more

Dawnzera: First RNA-Targeted Therapy to Prevent Hereditary Angioedema Attacks

Dawnzera (donidalorsen) is a new medicine approved to help prevent attacks of a rare genetic swelling disorder known as hereditary angioedema (HAE) in people aged 12 or older. Affecting about 7,000 people in the U.S.,… Read more

Papzimeos: First Approved Immunotherapy for Recurrent Respiratory Papillomatosis in Adults

Papzimeos (zopapogene imadenovec-drba) is a new type of immunotherapy approved to treat adults with recurrent respiratory papillomatosis (RRP). RRP is a rare condition caused by certain types of human papillomavirus (HPV), which leads to non-cancerous… Read more

Brinsupri: First Once-Daily Tablet for Non-Cystic Fibrosis Bronchiectasis

Brinsupri (brensocatib) is a new oral medicine approved to treat a long-term lung disease known as non-cystic fibrosis bronchiectasis (NCFB) in adults and children ages 12 or older. It works by blocking an enzyme called… Read more

Hernexeos (Zongertinib) Approved as the First Oral Targeted Treatment for HER2-Mutant Advanced Lung Cancer

Hernexeos (zongertinib) is a new pill for adults with a type of advanced lung cancer called non-small-cell lung cancer (NSCLC) that has a HER2 gene mutation that causes the cancer to grow and spread faster,… Read more

Aqvesme: FDA Approves First Pill for Treating Anemia in Adults With Alpha- or Beta- Thalassemia

Aqvesme (mitapivat) is a new oral medicine approved by the FDA for treating anemia in adults with alpha- or beta-thalassemia, including those who need and those who don’t require regular blood transfusions. Thalassemia is a… Read more

Wakix: FDA Expands Approval to Treat Sudden Muscle Weakness in Children With Narcolepsy

Wakix (pitolisant) is a prescription medication used to treat narcolepsy, a long-term neurological sleep disorder that causes excessive daytime sleepiness and, in many cases, cataplexy (sudden muscle weakness triggered by strong emotions). The FDA has… Read more